Akaal Pharma extends collaboration with GVK BIO
Posted on02 Jul 2015
Comments0
The collaboration is for formulations development services to support phase II clinical studies for topical treatment of Psoriasis GVK BIO has announced... Read More
+91-98 455 710 46 | info@nckpharma.com
Sign In
|Sign Up
Please sign in first
Not a member?
Please simply create an account before buying/booking any courses.
Create an account for free!
- Home
- NCK services
- Course List
- Admission
- Course Quick Glance
- Features of Online Courses
- Course Catalogue
- Course Application form
- Admission Notification & Special Offers
- Frequently asked question related to KPE courses
- Prospect Identification Process
- Final Examination Registration
- How to change / reset password?
- Course Upgrade
- Verify Course Certificate
- Request for Course Completion Certificate
- Corporate Training
- Knowledge Base
Tag
Akaal Pharma
Our Popular Courses
Recent Articles
- What is the meaning of pharmaceutical profiling?
- What is phase zero study? What it’s significance?
- Sanofi-kymab-deal: Sanofi’s acquisition of a clinical-stage biopharmaceutical company Kymab
- Covishield received emergency use authorization in India
- Glenmark introducing Remogliflozin + Vildagliptin combination first time in India
- Myovant and Pfizer’s $4.2 Billion Deal for Orgovyx
- Insight on Aurobindo and COVAXX exclusive licensing agreement
- Pfizer, BioNTech covid vaccine approval tilldate
- Chugai received MHLW, Japan marketing authorization for humanized anti-PD-L1 monoclonal antibody, Tecentriq to treat unresectable advanced/recurrent NSCLC
- Lynparza received marketing authorization by MHLW, Japan to treat advanced ovarian, prostate and pancreatic cancers
- AstraZeneca – Alexion $39 billion deal
- UK approves Pfizer-BioNTech’s COVID-19 vaccine. Rollout in week time
- Saudi Arabia signs non-binding vaccine agreement with CureVac
- Telix Pharma to acquire TheraPharm GmbH
- Case Study: Clinical basis of MHLW approval of Astellas’s Evrenzo to treat anemia of CKD in adult patients not on dialysis
- Covid 19 Vaccine development and commercialization status | More than 50 vaccine candidate under development
- PostEra codevelopment deal with NeuroLucent for Alzheimer’s disease
- AbbVie, Eisai received new indication approval for Humira to treat pyoderma gangrenosum
- Pfizer submitted application for emergency use of Covid vaccine
- Take Self Competency Test in Esxport Documentation